Clinical Trials Sponsored by Shanghai Vitalgen BioPharma Co., Ltd.

Total 1295 results

Shanghai Vitalgen BioPharma Co., Ltd.

Not yet recruiting

Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy

Bietti Crystalline Dystrophy

China
Shanghai Vitalgen BioPharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b

Glutaric Acidemia Type I | Glutaric Aciduria Type I

China
Shanghai Vitalgen BioPharma Co., Ltd.

Not yet recruiting

Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study

Hemophilia B
Shanghai Vitalgen BioPharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients

Hemophilia B

China
Shanghai Jiao Tong University School of Medicine
Shanghai Vitalgen BioPharma Co., Ltd.

Recruiting

An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.

Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

China
Xinhua Hospital, Shanghai Jiao Tong University...
Shanghai Vitalgen BioPharma Co., Ltd.

Recruiting

An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease

Type II Gaucher Disease

China
Institute of Hematology & Blood Diseases Hospital...
Shanghai Vitalgen BioPharma Co., Ltd.

Recruiting

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

Thalassemia Major | Thalassemia, Beta

China
Shanghai Blueray Biopharma Co., Ltd.

Not yet recruiting

Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | Advanced Cancer | Peripheral T Cell Lymphoma
Etern BioPharma (Shanghai) Co., Ltd

Not yet recruiting

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors (FIRST)

Advanced Solid Tumor

United States
Etern BioPharma (Shanghai) Co., Ltd

Recruiting

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
RetroLead (Shanghai) BioPharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects

Human Immunodeficiency Virus-1 (HIV-1) Infection
Etern BioPharma (Shanghai) Co., Ltd

Recruiting

FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors (FLIGHT)

Advanced Solid Tumor

China
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
Elpiscience Biopharma, Ltd.
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumor | Malignant Tumor

China
L & L biopharma Co., Ltd., Shanghai China

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001） (MEETCD8-001)

Solid Tumor

China
L & L biopharma Co., Ltd., Shanghai China

Recruiting

A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

Lymphoma | Solid Tumor

China
Shanghai Zhimeng Biopharma, Inc.
Tigermed Consulting Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB

Hepatitis B, Chronic

China
WestVac Biopharma Co., Ltd.
WestVac Biopharma (Guangzhou) Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

COVID-19

China
Hangzhou Valgen Medtech Co., Ltd

Not yet recruiting

DragonFly EU Pivotal Study

Mitral Valve Insufficiency
Hangzhou Valgen Medtech Co., Ltd

Recruiting

Safety and Effectiveness Study of Dragonfly System for Functional Mitral Regurgitation

Mitral Regurgitation Functional

China
Hangzhou Valgen Medtech Co., Ltd

Enrolling by invitation

Dragonfly-M Early Feasibility Study

Mitral Regurgitation

China
Hangzhou Valgen Medtech Co., Ltd

Unknown

Safety and Performance Study of the MitralStitch Repair System.

Mitral Regurgitation

China
Hangzhou Valgen Medtech Co., Ltd

Recruiting

Feasibility Study of the DragonFly-T System for Severe Tricuspid Regurgitation

Tricuspid Regurgitation

China
Hangzhou Valgen Medtech Co., Ltd

Not yet recruiting

Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation

Tricuspid Regurgitation

China
Hangzhou Valgen Medtech Co., Ltd

Active, not recruiting

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy

China
Hangzhou Valgen Medtech Co., Ltd

Enrolling by invitation

Feasibility Study of Dragonfly System for Severe Tricuspid Regurgitation

Tricuspid Regurgitation

China
Hangzhou Valgen Medtech Co., Ltd

Not yet recruiting

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy

China
Hangzhou Valgen Medtech Co., Ltd

Enrolling by invitation

Safety and Effectiveness Study of Dragonfly System for Degenerative Mitral Regurgitation

Degenerative Mitral Valve Disease

China
Newsoara Biopharma Co., Ltd.

Not yet recruiting

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

NSCLC Stage IV
Ausper Biopharma Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and Chronic Hepatitis B Patients

Hepatitis B, Chronic

China
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
Newsoara Biopharma Co., Ltd.

Recruiting

Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects

T2DM (Type 2 Diabetes Mellitus)

China
Genor Biopharma Co., Ltd.

Recruiting

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Advanced Breast Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer

China
Haihe Biopharma Co., Ltd.

Recruiting

Evaluate the Safety and Clinical Activity of HH2853

Advanced Solid Tumor | Epithelioid Sarcoma | Peripheral T Cell Lymphoma | FL Lymphoma

China, United States
Genor Biopharma Co., Ltd.

Recruiting

A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive

Cervical Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

B-cell Non-Hodgkin's Lymphoma

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Genor Biopharma Co., Ltd.

Recruiting

Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (GB226)

Lymphoma | Advanced Solid Tumor | Recurrent Solid Tumor | Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma

China
TJ Biopharma Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndromes(MDS)

China
TJ Biopharma Co., Ltd.

Withdrawn

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

First-line Non-small-cell Lung Cancer | First-line Urothelial Carcinoma | Second-line Urothelial Carcinoma | Second-line Melanoma

China
Advagene Biopharma Co. Ltd.

Completed

Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19

COVID-19

Taiwan
Haihe Biopharma Co., Ltd.

Terminated

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Melanoma | Erdheim-Chester Disease | Non-Small-Cell Lung Cancer | Advanced Tumors | Other RAS/RAF/MEK/ERK Mutated Tumors

United States, China
Haihe Biopharma Co., Ltd.

Terminated

First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors

Advanced Solid Tumors

China, Australia
Haihe Biopharma Co., Ltd.

Completed

Single Dose Glumetinib in Healthy Chinese Male Subjects

Healthy Volunteers

China
Newsoara Biopharma Co., Ltd.

Completed

Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus

Ileus

China
Genor Biopharma Co., Ltd.

Unknown

Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.

Brain Tumor

China
Genor Biopharma Co., Ltd.

Unknown

Phase Ⅰ Clinical Study Protocol of GB223 Monoclonal Antibody Injection

Bone Tumor

China
Centaurus Biopharma Co., Ltd.

Unknown

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Diffuse Large B Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Mantle Zone Lymphoma Refractory/Recurrent | Follicle Centre Lymphoma Diffuse

China

Clinical Trials Sponsored by Shanghai Vitalgen BioPharma Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations